More Than Just Words
More Than Just Words is a multiyear initiative in the US to drive toward health equity in breast cancer where there is an unmet need.
Reimagining Medicine for Patients With Breast Cancer
Reimagining Medicine for Patients With Breast Cancer
Alpelisib Mechanism of Action
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
Explore Clinical Trials
Explore Clinical Trials
Adjuvant HER2+
EPIK-B2
Trastuzamab + Pertuzumab + Alpelisib as Maintenance Therapy in PIK3CA Mutated HER2+ Advanced Breast Cancer
Advanced TNBC
EPIK-B3
Alpelisib Plus Nab-pacitaxel in Patients With Advanced Triple-Negative Breast Cancer With PIK3CA Mutation or PTEN Loss Without PIK3CA Mutation
HGSOC
EPIK-O
Alpelisib + Olaparib in Platinum-Resistant or Refractory, Germline BRCA Mutation Negative High-grade Serous Ovarian Cancer
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Explore Compounds
Explore Compounds
PI3K small-molecule inhibitor
LAG-3 receptor-targeting monoclonal antibody
PD-1–targeting monoclonal antibody
